Deoxyshikonin

Deoxyshikonin increases the expression of VEGF-C and VEGF-A mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction and binds to specific DNA sequences targeted by HIF. Deoxyshikonin inhibited colorectal cancer (CRC) through the PI3K/Akt/mTOR pathway. Deoxyshikonin has proangiogenesis effect and antitumor activity. Deoxyshikonin is an antibacterial agent against methicillin-resistant S. aureus (MRSA) and S. pneumonia (MIC=17 μg/mL) [1][2][3].

Product Specifications

CAS Number

[43043-74-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Bacterial; HIF/HIF Prolyl-Hydroxylase; PI3K

Type

Natural Products

Related Pathways

Anti-infection; Apoptosis; Metabolic Enzyme/Protease; PI3K/Akt/mTOR

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/deoxyshikonin.html

Concentration

10mM

Purity

99.96

Solubility

DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1C(CC/C=C(C)/C)=CC(C2=C1C(O)=CC=C2O)=O

Molecular Formula

C16H16O4

Molecular Weight

272.30

Precautions

H302, H315, H319, H335

References & Citations

[1]Prangsaengtong O, et al. Enhancement of Lymphangiogenesis In Vitro via the Regulations of HIF-1α Expression and Nuclear Translocation by Deoxyshikonin. Evid Based Complement Alternat Med. 2013;2013:148297.|[2]Zhang S, et al. Antibacterial effects of Traditional Chinese Medicine monomers against Streptococcus pneumoniae via inhibiting pneumococcal histidine kinase (VicK) . Front Microbiol. 2015 May 20;6:479.|[3]Yuzhen Zhu, et al. Deoxyshikonin isolated from Arnebia euchromainhibits colorectal cancer by down-regulating the PI3K/Akt/mTOR pathway. Pharm Biol. 2019 Dec;57 (1) :412-423.